Marinomed Biotech AG (WBO:MARI) Cyclically Adjusted PB Ratio: (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:MARI Marinomed Biotech AG WBO:MARI
42 GF Score
Price €5.40
GF Value €19.01
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Marinomed Biotech AG Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Marinomed Biotech AG  (WBO:MARI) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Marinomed Biotech AG Cyclically Adjusted PB Ratio Related Terms


Marinomed Biotech AG Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Marinomed Biotech AG's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marinomed Biotech AG Cyclically Adjusted PB Ratio Chart

Marinomed Biotech AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Marinomed Biotech AG Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

WBO:MARI vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Marinomed Biotech AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marinomed Biotech AG Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Marinomed Biotech AG's Cyclically Adjusted PB Ratio falls into.


WBO:MARI
42GF Score
Marinomed Biotech AG WBO:MARI
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marinomed Biotech AG Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Marinomed Biotech AG's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Marinomed Biotech AG's adjusted Book Value per Share data for the fiscal year that ended in Dec25 was:

Adj_Book=Book Value per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=-3.816/140.3500*140.3500
=-3.816

Current CPI (Dec25) = 140.3500.

Marinomed Biotech AG Annual Data

Book Value per Share CPI Adj_Book
201612 -1.701 102.092 -2.338
201712 -3.229 104.291 -4.345
201812 -10.448 106.291 -13.796
201912 7.367 108.091 9.566
202012 3.625 109.321 4.654
202112 0.129 113.971 0.159
202212 -2.751 125.541 -3.076
202312 -8.242 132.570 -8.726
202412 -14.655 135.273 -15.205
202512 -3.816 140.350 -3.816

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Marinomed Biotech AG (WBO:MARI) Overvalued in 2026?

Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued. The current stock price of €5.40 is trading 71.6% below its estimated GF Value™ of €19.01. GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.

Key valuation signals for WBO:MARI:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €19.01 vs. price of €5.40 (71.6% below fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the WBO:MARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Marinomed Biotech AG Business Description

Other Exchanges 93Z:Germany
Address Hovengasse 25, Korneuburg, AUT, 2100
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
42GF Score

Get the complete analysis for WBO:MARI

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.40
Price
€19.01
GF Value